the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma
evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.
Hepatocellular Carcinoma
PROCEDURE: transarterial infusion
OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months
ORR, object response rate, From date of randomization until the date of death from any cause, assessed up to 60 months|PFS, progression-free survival, From date of randomization until the date of progress from any cause, assessed up to 60 months
evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.